We are live on ! Find out more
CPHI icon

China Pharma Holdings
CPHI

9 hedge funds and large institutions have $362K invested in China Pharma Holdings in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

13% more funds holding

Funds holding: 8 → 9 (+1)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.01% less ownership

Funds ownership: 0.01% → 0.01% (-0.01%)

18% less capital invested

Capital invested by funds: $443K → $362K (-$81K)

Holders
9
Holders Change
+1
Holders Change %
+12.5%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAM
Panagora Asset Management
Massachusetts
+$47.2K
2
Citadel Advisors
Citadel Advisors
Florida
+$40.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$17K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$6.61K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$4.65K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$9.83K
2
VF
Virtu Financial
New York
-$6.08K
3
TSS
Two Sigma Securities
New York
-$2K

CPHI Hedge Fund Activity: Q1 2018 in Review

9 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q1 2018, worth a combined $362K — down 18% from $443K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CPHI positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Panagora Asset Management, opening a new position worth an estimated $47.2K. The largest seller was UBS Group, cutting an estimated $9.83K.

  • 9 institutional investors held China Pharma Holdings (CPHI) as of Q1 2018, up from 8 in Q4 2017.
  • Funds reported $362K of China Pharma Holdings stock for Q1 2018, down 18% quarter-over-quarter.
  • 3 funds opened new China Pharma Holdings positions in Q1 2018 and 1 closed out, a net change of +2 holders.
  • The largest China Pharma Holdings buyer in Q1 2018 was Panagora Asset Management, an estimated $47.2K added.
  • The largest China Pharma Holdings seller in Q1 2018 was UBS Group, an estimated $9.83K sold.

Based on aggregated 13F filings for Q1 2018.